Fintel reports that on December 16, 2025, HC Wainwright & Co. reiterated coverage of Emergent BioSolutions (NYSE:EBS) with a Buy recommendation. Analyst Price Forecast Suggests 11.68% Upside As of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback